As part of the International Liver Congress (ILC) 2021, the EASL Takeaways take a look at key topics from the congress, with leading experts discussing the most impactful science and putting it into perspective. In this session join Professors Pierre-Emmanuel Rautou Didier Samuel and Andrés Cárdenas as they discuss key questions in liver cirrhosis and its complications from ILC 2021.
Professor Samuel first explains the effectiveness of anticoagulants in patients with chronic portal vein hypertension without cirrhosis. The panel then explores whether anticoagulants should be used in patients with portal vein thrombosis and cirrhosis, despite the increased risk of bleeding found in patients with chronic liver disease. In the second half of the session, Professor Samuel leads a discussion on the novel DIALIVE liver dialysis device in patients with ACLF, including how it works, its effectiveness and its limitations.
|Dr. Didier Samuel, MD, PhD, is Professor of Hepatology and Gastroenterology at Université Paris-Saclay, Villejuif, France and he is currently Dean of the Faculty of Medicine Paris-Saclay. Prof Samuel is also Medical Director of the Liver Transplant Program, and Head of both the Liver and Intensive Care Units at Centre Hepatobiliaire of Universitary Hôpital Paul Brousse in Villejuif. He is Director of Inserm Research Unit 1193 at Université Paris-Saclay. His research focuses on liver transplantation, viral hepatitis, liver failure and hepatocellular carcinoma. He was a member of the Council of the International Liver Transplantation Society from 2007 to 2015 (ILTS, acting as President 2013-2014), and of the Scientific Committee of the European Association of the Study of the Liver (EASL, 2000-2003). He served as Editor-in-Chief of Journal of Hepatology (2010-2014).|
|Andrés Cárdenas is a Staff Member and Consultant of the Institute of Digestive Diseases and Metabolism at Hospital Clinic Barcelona and Associate Professor of Medicine at the University of Barcelona. Professor Cárdenas is also a member of the EASL Educational Committee. His main expertise and research interests are cirrhosis and its complications, interventional procedures in patients with cirrhosis and portal hypertension and biliary complications in liver transplant recipients.|
|Pierre-Emmanuel Rautou is a clinical specialist in Hepatology with a PhD in vascular biology and is the head of the splanchnic hemodynamic laboratory at Beaujon Hospital, France. He is also the chair of the EASL Scientific Committee. His research is focused on the role of vessels in liver diseases with specific interests in primary vascular liver diseases as well as in vascular involvement in common liver diseases development and complications.|